|Bid||0.3001 x 400|
|Ask||0.3049 x 100|
|Day's Range||0.2980 - 0.3240|
|52 Week Range||0.2600 - 2.2800|
|PE Ratio (TTM)||-0.48|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
The The Woodlands, Texas-based company said it had a loss of 8 cents per share. The biopharmaceutical company posted revenue of $7,000 in the period. The company's shares closed at 35 cents. A year ago, ...
Lack of revenues in Repros Therapeutics' (RPRX) product portfolio could be a concern. But the company's most advanced pipeline candidates -- enclomiphene and Proellex -- might better its results in Q2.
Repros Therapeutics Inc. (RPRX) announced that its pipeline candidate Proellex which is being evaluated for uterine fibroids will remain on partial clinical hold.